Drug intelligence / Profile preview

BRY104

Development stage: Unknown
Lead developer: Bryleos
Modality: Peptides
Administration: Oral

Overview

BRY104 is an investigational oral peptide drug candidate being developed by Bryleos. It is formulated using the company's proprietary LathMize green chemistry and physical pharmacy platform, which is designed to enhance the shelf stability, metabolic resilience, and oral bioavailability of fragile endogenous molecules. BRY104 is currently in preclinical development as a 505(b)(1) Investigational New Drug (IND) candidate.

Beyond the preview

Go deeper on BRY104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRY104.

Explore the full profile